BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:53 PM
 | 
May 31, 2007
 |  BC Extra  |  Company News

FDA accepts methylnaltrexone NDA

FDA accepted for filing an NDA for subcutaneous methylnaltrexone (MNTX) from Progenics (PGNX) to treat opioid-induced constipation (OIC) in patients receiving palliative care. The...

Read the full 103 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >